Prognosis. K. PERFORMANCE OBJECTIVES AND OUTCOMES – CONTRACTOR shall be required to meet the following performance Objectives and Outcomes:
Prognosis. 5. Statement that following a review of the job description, the patient is totally disabled or fit for light duties (duties and any time constraints to be identified).
Prognosis. 3. Estimated Duration:
Prognosis. Note probable duration and expected results of current treatment.
Prognosis iii. Client’s plan for continued recovery including support systems and plans for relapse prevention.
Prognosis. 5 p. SUBSTANCE USE SCREENING
Prognosis. Demodectic mange is not an inherited condition, but the suppressed immune system that allows the puppy to be susceptible to the mites can be Sarcoptic Mange Although next to impossible to diagnose at vet, it is pretty easy to diagnose demodectic vs. sarcoptic mange just by looking and smelling the dog. Demodectic mange does not smell, hair loss but no scabs, and does not make dog itch. Sarcoptic mange smells funky, and at times is accompanied by secondary infection. Dogs will scratch relentlessly with sarcoptic mange, and are usually scabby along with hairloss. Sarcoptic mange, commonly known as canine scabies, is caused by a small mite. These microscopic mites can invade the skin of healthy dogs or puppies and create a variety of skin problems, the most common of which is hair loss and severe itching. While they will infect other animals and even humans, they prefer to live their short lives on dogs. Who gets sarcoptic mange? Sarcoptic mange can infect all ages and breeds of dogs. While it prefers to live on dogs, this particular mite will also infect cats, ferrets, humans, and fox. What is the life cycle of Sarcoptes scabiei? The mites usually spend their entire life on a dog. The female mite xxxxxxx into the skin and lays eggs several times as she continues burrowing. These tunnels can actually reach the length of several centimeters. After she deposits the eggs, the female mite dies. In 3-8 days, the eggs hatch into larvae which have 6 legs. The entire life cycle requires 2-3 weeks. The mites prefer to live on the dog, but will live for several days off of the host in the environment. In cool moist environments, they can live for up to 22 days. At normal room temperature in a home, they will live from 2 to 6 days. Because of the mite's ability to survive off the host, dogs can become infected without ever coming into direct contact with an infected animal. What are the symptoms? Usually include hair loss and severe itching especially on the elbows, ears, armpits, hocks, chest, and ventral abdomen (belly). The mites prefer to live on areas of the skin that have less hair. As the infection worsens it can spread over the entire body. Small red pustules often develop along with yellow crusts on the skin. Because of the severe itching and resultant scratching, the skin soon becomes traumatized and a variety of sores and infections can develop as a result. The itching seems to be much worse in warm conditions such as indoors or near a stove or heat vent. How...
Prognosis. Prognosis for VC patients is generally good, with an overall five-year survival of 70%. An early diagnosis of VC is important for improved prognosis (6, 9). Five-year survival is 80-90% for patients who present with early-stage VC, regardless of tumour diameter and expansion to the vagina and/or urethra (6, 15, 32, 34). This decreases to 25-67% if groin lymph nodes are affected, largely depending on the number of involved lymph nodes and their growth pattern (6, 9, 12, 32). Five-year survival is 75% for patients with one or two lymph node metastases and decreases to 24% for patients with five or six involved lymph nodes (8). Patients with extranodal growth of a lymph node metastasis Chapter 1 have a 5-year survival of 34% compared to 66% for patients with intranodal growth (12). VC related mortality usually results from failure to control the disease once it has progressed beyond the site of origin. In these patients diagnosis is often delayed by the patient or physician (6). For patients with a local recurrence disease-specific survival decreases from 90% to 69% (35). Furthermore, disease-specific survival is worse for patients who develop a local recurrence within two years compared to patients that develop a local recurrence more than two years after primary treatment (53% versus 76%) (35, 36). The majority of groin recurrences (~ 70%) develop within the first year after primary treatment, with a median time until recurrence of 7 months (35, 37, 38). Prognosis for patients with a groin recurrence is very poor. Most patients die of disease within two years after development of the groin recurrence (25, 34, 35, 38). On the contrary, a recently published study found an overall survival rate of 50% for 30 patients with a groin recurrence after 7 years. Especially patients who received multimodal treatment for their groin recurrence performed better (39). Local recurrence Recurrent disease is an important clinical challenge in the treatment of VC. Despite all developments in treatment strategies, recurrence rates of VC are still high: 12-37% of VC patients develop a recurrence (25, 26, 40) of which 50% are local (25, 26, 37, 40). There are several known risk factors for a local recurrence. The width of the tumour free margin is considered the most important predictive factor for local recurrences. It is known that tumour-positive margins are associated with recurrence and poor prognosis. The minimal safe tumour-free margin is one of the most relevant clinica...
Prognosis. The prognosis of colorectal cancer patients from HNPCC families appears to be more favourable than that of sporadic CRC patients, with overall 5 years and 10 years survival rates of 65% vs. 44%, and 68% vs. 37%, respectively181, 254, 327. It has been hypothesized that this is caused by a higher sensitivity to chemotherapy of mismatch repair deficient tumours99, 115. However, a recent study did not show benefit of fluorouracil-based adjuvant chemotherapy in patients with MSI-High tumours242. Also, MMR-deficient cells are tolerant to alkylating chemotherapeutics. Another possible explanation for the increased survival in HNPCC-associated colorectal cancer is the Introduction 35 enhanced immune-response to the highly genetically unstable MSI tumours250, 251. Xxxxx et al.34 assumed that the abundant presence of immune cells in MMR-mutant tumours increases oxidative stress. Vulnerability of MMR-deficient cells to oxidative stress may cause cell cycle arrest and lead to a more favourable prognosis. No difference in survival of endometrial cancer was found between HNPCC-related and sporadic patients23.
Prognosis. Patient prognosis may influence the interest of potential participants, with around 40% of non-consenters to a 2011 study on research in hospice and palliative care citing wanting to spend time with their families as they are approaching death as a reason for not participating in research at the end of life (32). Researchers have raised the issue that palliative care research is too time consuming for patients who may have other matters to attend to and limited energy to execute those matters with as their illnesses or conditions continue to advance; however, palliative care study follow-ups have found that patients and their families did not perceive the time burden of study participation to be too great (17, 26).
